Former Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three late-stage drugs saw their hopes dashed as 2020 drew to a close.
Gilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment with its Veklury antiviral, and its latest financial results reveal the benefit of that a
Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like gene therapy Zolgensma gathered pace.
German vaccine firm CureVac has been awarded a €75 million loan from the European Investment Bank to boost its manufacturing capacity for its potential COVID-19 vaccine.
Biopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised a record-breaking $2.2 billion from the sale of 77 million s
The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right (CVR) deal with Bristol-Myers Squibb have risen sharply, aft